Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.…
Nordic outperformance widens, US biotech retreats sharply
Elicera Therapeutics (STO: ELIC) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 2.465 SEK on 20 November 2026, down 54.5% over 52 weeks. Its 52-week range is 2.245 SEK to 7.000 SEK: the price is 64.8% below the high and 9.8% above the low.
Its market capitalisation is 164.51M SEK.
Elicera Therapeutics reports return on equity of -74.5% and an operating margin of -236.2%.
It holds more cash than debt, a net cash position of 58.13M SEK. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 7.300 SEK is 196.1% above the current price.